Recombinant Human Methionine Synthase Reductase (MTRR) Protein (GST)

Name: Recombinant Human Methionine Synthase Reductase (MTRR) Protein (GST)
Brand: Beta LifeScience
SKU: BLC-08658P
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Methionine Synthase Reductase (MTRR) Protein (GST) is produced by our E.coli expression system. This is a full length protein.
Purity	Greater than 90% as determined by SDS-PAGE.
Uniprotkb	Q9UBK8
Target Symbol	MTRR
Synonyms	MTRR; Methionine synthase reductase; MSR; EC 1.16.1.8
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-GST
Target Protein Sequence	MGAASVRAGARLVEVALCSFTVTCLEVMRRFLLLYATQQGQAKAIAEEICEQAVVHGFSADLHCISESDKYDLKTETAPLVVVVSTTGTGDPPDTARKFVKEIQNQTLPVDFFAHLRYGLLGLGDSEYTYFCNGGKIIDKRLQELGARHFYDTGHADDCVGLELVVEPWIAGLWPALRKHFRSSRGQEEISGALPVASPASSRTDLVKSELLHIESQVELLRFDDSGRKDSEVLKQNAVNSNQSNVVIEDFESSLTRSVPPLSQASLNIPGLPPEYLQVHLQESLGQEESQVSVTSADPVFQVPISKAVQLTTNDAIKTTLLVELDISNTDFSYQPGDAFSVICPNSDSEVQSLLQRLQLEDKREHCVLLKIKADTKKKGATLPQHIPAGCSLQFIFTWCLEIRAIPKKAFLRALVDYTSDSAEKRRLQELCSKQGAADYSRFVRDACACLLDLLLAFPSCQPPLSLLLEHLPKLQPRPYSCASSSLFHPGKLHFVFNIVEFLSTATTEVLRKGVCTGWLALLVASVLQPNIHASHEDSGKALAPKISISPRTTNSFHLPDDPSIPIIMVGPGTGIAPFIGFLQHREKLQEQHPDGNFGAMWLFFGCRHKDRDYLFRKELRHFLKHGILTHLKVSFSRDAPVGEEEAPAKYVQDNIQLHGQQVARILLQENGHIYVCGDAKNMAKDVHDALVQIISKEVGVEKLEAMKTLATLKEEKRYLQDIWS
Expression Range	1-725aa
Protein Length	Full Length
Mol. Weight	107.4kDa
Research Area	Metabolism
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Key enzyme in methionine and folate homeostasis responsible for the reactivation of methionine synthase (MTR/MS) activity by catalyzing the reductive methylation of MTR-bound cob(II)alamin. Cobalamin (vitamin B12) forms a complex with MTR to serve as an intermediary in methyl transfer reactions that cycles between MTR-bound methylcob(III)alamin and MTR bound-cob(I)alamin forms, and occasional oxidative escape of the cob(I)alamin intermediate during the catalytic cycle leads to the inactive cob(II)alamin species (Probable). The processing of cobalamin in the cytosol occurs in a multiprotein complex composed of at least MMACHC, MMADHC, MTRR and MTR which may contribute to shuttle safely and efficiently cobalamin towards MTR in order to produce methionine. Also necessary for the utilization of methyl groups from the folate cycle, thereby affecting transgenerational epigenetic inheritance. Also acts as a molecular chaperone for methionine synthase by stabilizing apoMTR and incorporating methylcob(III)alamin into apoMTR to form the holoenzyme. Also serves as an aquacob(III)alamin reductase by reducing aquacob(III)alamin to cob(II)alamin; this reduction leads to stimulation of the conversion of apoMTR and aquacob(III)alamin to MTR holoenzyme.
Subcellular Location	[Isoform B]: Cytoplasm.; [Isoform A]: Cytoplasm.
Database References	HGNC: 7473 OMIM: 236270 KEGG: hsa:4552 STRING: 9606.ENSP00000264668 UniGene: PMID: 30004262 The gene polymorphism of MTRR A66G may not be an independent genetic risk factor in deep venous thrombosis in China. PMID: 29927730 The genotypes of three women having spina bifida fetuses from two unrelated Chinese families were screened in candidate alleles. A trinucleotide deletion (c.4_6delAGG) was found in the first exon of MTRR only in the affected women, but not in their siblings with healthy babies or in controls. The Arg2del variant's subcellular localization and catalysis was unchanged, but it failed to efficiently activate MTR. PMID: 28712006 Our results suggest an association between underweight and early childhood caries; in addition it is suggested that MTRR is a common genetic risk factor for early childhood caries and underweight PMID: 28118645 higher frequency of 66GG genotype and 66G allele of MTRR 66A > G polymorphism observed in the women with pre-eclampsia compared to control group PMID: 27806663 An association between the MTRR A66G polymorphism and LC ( p = 0.042) was found. In addition, this allele was observed more frequently in smokers compared to nonsmokers ( p = 0.030). In contrast, the distribution of the MTR 2756A>G and the MTRR 524 C> T allele frequencies were similar in the subject cases and controls. PMID: 28537809 Meta-analysis suggests that MTRR 66A>G polymorphism may be associated with oligoasthenozoospermia risk. PMID: 28436330 Study in Egyptian children showed that MTRR A66G and C524T polymorphisms were associated with a higher congenital heart diseases risk in the homozygote comparison of wild and mutant genotypes and also in heterozygote and mutant comparison. PMID: 28778621 study widens the clinical, molecular, metabolic, and cytological knowledge of deficiency MTRR enzyme. PMID: 25978498 The present study suggests that the G allele of MTR A2756G polymorphism is associated with an increased risk of autism. PMID: 28094822 These findings indicate that the alternatively spliced form of MS expressed in SH-SY5Y human neuronal cells is sensitive to inhibition by thimerosal and neurotoxic metals, and lower GSH levels contribute to their inhibitory action. PMID: 26989453 MTRR genetic polymorphisms are risk factor for predicting cardiovascular manifestations in Marfan syndrome. PMID: 26063524 no association of rs1801394 with non-obstructive azoospermia PMID: 26196053 an association between MTRR 66 and SHMT1 1420 polymorphisms and spaceflight-induced vision changes PMID: 26316272 Results identified an allelic variant in the first intron of MTRR that is associated with increased risk of anencephaly in neural tube defects cases. PMID: 26045171 Findings indicate an association between the single-nucleotide polymorphism A66G in the synthase reductase (MTRR A66G) gene and male infertility, particularly in oligoasthenozoospermia males. PMID: 25966116 The findings of this study provide evidence that multiple sclerosis spinal cord simultaneously lack Cbl, EGF, and PrPCs. PMID: 25888933 Results from the case-control study and meta-analysis suggest that both of the two polymorphisms MTHFR C677T and MTRR A66G Polymorphisms are not associated with being overweight/obesity PMID: 26016497 A decrease of placental expression was noted for MTRR by 50% in pre-eclamptic women as compared to control group. PMID: 25801727 MTRR 66GG genotype showed strong negative association with the risk of childhood brain tumors. PMID: 25809864 More specifically, variants in methionine synthase reductase (MTRR) are not likely associated with capecitabine efficacy. PMID: 25815774 The MTRR polymorphism represents a risk factor for the birth of a child with Down Syndrome among white Caucasian women. [Meta-analysis] PMID: 24965145 MSR 524C/T polymorphism is associated with essential hypertension in ethnic groups in China. PMID: 26252105 Review/Meta-analysis: suggest an association between MTRR A66G polymorphism and colorectal cancer susceptibility among Caucasians. PMID: 26214647 meta analysis demonstrated that MTRR A66G polymorphism is a risk factor for congenital heart defects PMID: 24913415 Heterogeneity across alcohol consumption status of the associations between MTR/MTRR polymorphisms and these cancers indicates potential interactions between alcohol drinking and one-carbon metabolic pathway PMID: 25337902 This meta-analysis suggests that MTRR A66G GG is associated with decreased risk of leukemia in a Caucasian population and in children, especially for ALL. PMID: 24261678 MTRR A66G polymorphisms have not been found to affect the hemostatic system in adolescents with Essential Hypertension. PMID: 25518505 MTRR A66G polymorphism was not associated with breast cancer susceptibility. PMID: 24815481 Reciprocal active site substitutions in CPR (H322A) and MSR (A312H) were created. Interflavin electron transfer was inhibited in CPR H322A and accelerated in MSR A312H. PMID: 24589657 MTRR A66G gene polymorphism is associated with meningioma. PMID: 23959833 Single nucleotide polymorphism in MTRR gene with LINE-1 methylation is associated with breast cancer. PMID: 24130171 The distribution of MTHFR A1298C and MTRR A66G genotypes were not different between the fertile and infertile groups. PMID: 24334125 [meta-analysis] MTRR A66G polymorphisms are not associated with risks for neural tube defects in Caucasian children. PMID: 23425389 The 66GG and AG genotypes were associated with decreased odds ratios for heart defects. This overall association was driven by decreased risk for ventricular septal defect for 66GG and AG and decreased odds ratio for aortic valve stenosis for 66AG. PMID: 22475273 A review of the influences of genetic polymorphisms in methionine synthase reductase on the occurrence of adverse effects from methotrexate therapy. PMID: 23986219 Haplotype analysis suggests an association between MTRR haplotypes and reduced risk of migraine with aura. PMID: 23430981 genetic association studies in population in China: Data suggest that an SNP in MTRR (C524T; S175L; rs1801394) is associated with decreased risk of Down syndrome in this population. PMID: 22925068 maternal MTRR 66A>G polymorphism is associated with an increased risk of having a DS child.[Meta-Analysis] PMID: 23094987 Rs6893114 in MTRR and alcohol consumption are associated with lung cancer risk in current smokers. PMID: 23372658 Results indicate the importance of four gastric cancer susceptibility polymorphisms of IL-10, NOC3L, PSCA and MTRR in the Chinese Han population. PMID: 22796266 The MTRR+66AA genotype may correlate with the severity of HD. PMID: 23039890 studies suggest that SNPs in CBS and MTRR have sex-specific associations with aberrant methylation in the lung epithelium of smokers that could be mediated by the affected one-carbon metabolism and transsulfuration in the cells PMID: 22665368 Known common single-nucleotide polymorphisms in MTRR and BHMT genes may not be significant risk factors for cororonary artery disease. PMID: 22339686 the single-nucleotide polymorphism A66G MTRR is not involved in the development of breast cancer. PMID: 22236648 The variant allele and genotypic frequencies in MTRR A66G gene was significantly higher in patients with UC compared to healthy controls. PMID: 21947961 MTRR A66G polymorphism is a potential biomarker for cancer risk. PMID: 21547363 MTRR A66G and cSHMT C1420T polymorphisms influence CpG island methylator phenotype of BNIP3, thus epigenetically regulating BNIP3 in breast cancer PMID: 21987236 We have demonstrated that the MTRR c.56+781 A>C variant is an important genetic marker for increased congenital heart disease risk because this variant results in functionally reduced MTRR expression at the transcriptional level. PMID: 22179537 MTRR polymorphisms did not appear to be an important genetic factor predisposing to idiopathic infertility in Brazilian men. PMID: 21775772

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.